Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial.
Berend J van der WilkBen M EyckM DoukasM C W SpaanderE J SchoonK K KrishnadathL E OostenbrugS M LagardeB P L WijnhovenL H J LooijengaK BiermannJ J B van LanschotPublished in: The British journal of surgery (2020)
Most residual disease after nCRT missed by endoscopic biopsies was located in the mucosa. Active surveillance could be improved by more sampling and considering submucosal biopsies.